Dementia, Progressive Supranuclear Palsy
Conditions
Keywords
PSP, dementia, neuropsychology, treatment
Brief summary
to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST 4. changes in motor activity are associated with changes in language and overall results of the in MMST
Interventions
DRUGrivastigmine
rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
Sponsors
University Hospital Tuebingen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* diagnosis of PSP * willingness to participate in the study * informed consent * ability to speak * no further CNS diseases * written informed consent * stable state of health * ability to give informed consent, will checked by an independent physician
Exclusion criteria
* alcohol abuses * acute psychosis * pregnancy or lactation * known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives * liver failure * known sick sinus syndrome or excitation disturbance * known ulcus ventriculi or duodenal ulcer * known asthma or COPD * seizures * renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improvement in neuropsychological assessments for memory and executive function, e.g. tested by Tower of London Test, CERAD Battery and Logical Memory Test (WMSR) | 6 month |
Secondary
| Measure | Time frame |
|---|---|
| changes in speech function and improvement of quality of life | 6 Month |
Countries
Germany
Contacts
Primary ContactDaniela Berg, Doctor
Backup ContactInga Liepelt, Doctor
Outcome results
None listed